Sanofi PE Ratio 2006-2018 | SNY

Current and historical p/e ratio for Sanofi (SNY) from 2006 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Sanofi PE ratio as of November 15, 2018 is 13.94.
Sanofi PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2018-11-15 44.57 25.61
2018-03-31 38.26 $1.74 21.99
2017-12-31 41.05 $3.65 11.25
2017-09-30 47.53 $3.92 12.12
2017-06-30 45.73 $3.92 11.67
2017-03-31 41.78 $3.98 10.50
2016-12-31 37.34 $2.04 18.30
2016-09-30 35.26 $2.40 14.69
2016-06-30 38.64 $2.22 17.40
2016-03-31 35.56 $2.05 17.35
2015-09-30 42.04 $1.80 23.35
2015-06-30 43.86 $1.65 26.58
2014-06-30 45.60 $2.01 22.69
2013-06-30 42.64 $2.38 17.92
2012-06-30 30.22 $3.21 9.41
2012-03-31 29.61 $3.23 9.17
2011-12-31 27.93 $3.54 7.89
2011-09-30 25.07 $3.05 8.22
2011-06-30 30.70 $2.85 10.77
2011-03-31 26.02 $3.14 8.29
2010-12-31 23.81 $3.15 7.56
2010-09-30 24.56 $3.56 6.90
2010-06-30 22.20 $3.97 5.59
2010-03-31 26.62 $4.36 6.11
2009-12-31 27.98 $4.21 6.65
2009-09-30 26.33 $3.68 7.15
2009-06-30 21.01 $3.17 6.63
2009-03-31 18.86 $2.97 6.35
2008-12-31 21.72 $4.03 5.39
2008-09-30 22.20 $4.75 4.67
2008-06-30 22.44 $4.99 4.50
2008-03-31 24.28 $4.51 5.38
2007-12-31 29.45 $3.12 9.44
2007-09-30 27.44 $2.58 10.64
2007-06-30 26.05 $2.40 10.85
2007-03-31 27.46 $2.68 10.25
2006-12-31 29.14 $2.60 11.21
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $112.613B $39.599B
Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing of healthcare products. Its strategy is built around three priorities to reach its goals and ensure sustainable growth. The priorities are: increasing innovation in Research and Development, adapting Group structures to future challenges and seizing external growth opportunities. Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. Sanofi-Aventis is headquartered in Paris, France.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $388.162B 18.20
Pfizer (PFE) United States $259.069B 14.60
Novartis AG (NVS) Switzerland $204.655B 17.49
Merck (MRK) United States $201.163B 17.43
AbbVie (ABBV) United States $132.702B 11.78
Eli Lilly (LLY) United States $119.057B 20.93
Novo Nordisk (NVO) Denmark $107.980B 17.54
AstraZeneca (AZN) United Kingdom $105.090B 13.05
GlaxoSmithKline (GSK) United Kingdom $102.669B 13.80
Bristol-Myers Squibb (BMY) United States $85.837B 14.14